With an oil price at the mid-USD60s/bbl level, focus on the oil major overspending situation, and resulting impact on the outlook for offshore-focused oil services, is set to increase further. While oil companies would likely cut, or even eliminate, buyback programmes first, we expect increased focus on spending reductions and efficiencies, creating a more challenging business environment for oil services. Hence, we see a risk of oil companies taking a more cautious approach, resulting in projec...
Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons Company Announcement COPENHAGEN, Denmark; April 1, 2025 – (Nasdaq: GMAB) – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to p...
TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer Media Release COPENHAGEN, Denmark; March 31, 2025 TIVDAK® is the first and only antibody-drug conjugate (ADC) approved to treat recurrent or metastatic cervical cancer with disease progression on or after systemic therapyIn the global Phase 3 innovaTV 301 clinical trial TIVDAK demonstrated superior overall survival compared to chemotherapyTIVDAK is approved for the treatment of recurrent or metastatic cervical cancer in the European Union, United States and Japan ...
Transactions in connection with share buy-back program Company Announcement COPENHAGEN, Denmark; March 31, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back program is expected to be completed no later than July 10, 2025. The following transactions were executed under the program from March 26 to March 28, 2025: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)March ...
TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy Media ReleaseCOPENHAGEN, Denmark; March 27, 2025 TIVDAK® is the first and only antibody-drug conjugate (ADC) approved for patients with advanced or recurrent cervical cancer in JapanApproval is based on results from the global Phase 3 innovaTV 301 trial, in which TIVDAK demonstrated superior overall survival compared to chemotherapyRising cervical cancer incidence and mortality rates in Japan signify ne...
Genmab Announces Initiation of Share Buy-Back Program Company Announcement Repurchase of up to 2.2 million shares with a maximum aggregate total value of DKK 4.0 billionReduce the capital of Genmab and honor our commitments under the Restricted Stock Unit programCompletion expected no later than July 10, 2025 COPENHAGEN, Denmark; March 25, 2025 – (Nasdaq: GMAB) announced today that it is initiating a share buy-back program, to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back program will be undertaken on the terms set out below and...
We expect Q1 to show similar trends to the most recent quarters, but negative FX translation effects (strengthening SEK) still result in cuts to our 2025–2027e EPS of 4–5%. We continue to see a robust transformation case, as the journey towards the 8% profit margin target by end-2025 continues, with our H2 2025e EBITA margin now at 7.8–7.9%. We reiterate our BUY, but have lowered our target price to SEK192 (200).
Millicom (Tigo) completes delisting from Nasdaq Stockholm and SEB informs Millicom of its intent to initiate the sale of shares not withdrawn from SDR program Millicom (Tigo) completes delisting from Nasdaq Stockholm and SEB informs Millicom of its intent to initiate the sale of shares not withdrawn from SDR program Luxembourg, March 24, 2025 – Millicom International Cellular S.A. (“Millicom”), has completed the delisting of its Swedish Depositary Receipts (SDRs) from Nasdaq Stockholm, in line with previous communications. The last day of trading was March 17, 2025. As of March 24, 2025...
In line with its earlier communication about Pemex looking for partners to re-start drilling activities and fight oil production decline, local news reports suggest that Pemex is seeking partnerships for 17 blocks (11 offshore and six onshore) to secure external capital. It is mostly considering local partners and intends to take the role as operator in most of the blocks. At first glance, the expected volume from the partnerships looks to be small, with only 66kbd to be added by year-end 2025. ...
Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc. Company Announcement AbbVie Inc. files complaint against Genmab in the U.S. District Court for the Western District of Washington (Seattle)Genmab categorically refutes allegations and will vigorously defend the company COPENHAGEN, Denmark; March 22, 2025 – (Nasdaq: GMAB) announced today thatAbbVie Inc. (AbbVie) has filed a complaint in the U.S. District Court for the Western District of Washington (Seattle) naming Genmab A/S; ProfoundBio US Co.; ProfoundBio (Suzhou) Co., Ltd.; and former AbbVi...
Notification of transaction by a closely associated person of a Director of Millicom (Tigo) Notification of transaction by a closely associated person of a Director of Millicom (Tigo) Luxembourg, March 20, 2025 – International Cellular S.A. ("Millicom") announces that, on March 17, 2025, Atlas S.A.S. (”Atlas”) a person closely associated (”PCA”) with Jules Niel, a member of Millicom’s Board of Directors, informed that it acquired 344,797 Millicom Swedish Depository Receipts (SDRs) in Nasdaq Stockholm (the “Acquisition”) at an average price of SEK 299.77 per SDR. The Acquisition by Atla...
After a slow start to the year for deepwater awards, we see long- and short-term jobs nearing rig selection. On the positive side, we believe the capital markets will appreciate increasing fixture activity and oil companies committing to long-term development jobs, supporting cycle duration. From a dayrate perspective, we see the bifurcation thesis unfolding, as some contractors are more focused on prioritising utilisation, also with counterparty, rig quality and region playing a role. Hence, as...
Following recent updates from E&P companies, we have reduced our 2025 offshore spending estimate to 0.5% (from c3% earlier this year). This is driven by a combination of actual 2024 spending being higher than expected (8% versus 4% previously), creating tougher comparables and a reduction in spending plans from Pemex in 2025. Despite growth flattening out, we still see the cycle building in duration, with execution of deepwater developments remaining on the agenda, albeit with a delayed executio...
Millicom’s Nomination Committee’s proposal for Board of Directors Millicom’s Nomination Committee’s proposal for Board of Directors Luxembourg, March 17, 2025 – In advance of the Annual General Meeting of shareholders (“AGM”) of Millicom International Cellular S.A. (“Millicom”), to be held on May 21, 2025, Millicom’s Nomination Committee proposes: The election of Pierre-Alain Allemand as new member of the Board of Directors; The re-election of Maxime Lombardini, Jules Niel, Pierre-Emmanuel Durand, María Teresa Arnal, Bruce Churchill, Blanca Treviño de Vega and Justine Dimovic as ...
Notification of transaction by a closely associated person of a Director of Millicom (Tigo) Notification of transaction by a closely associated person of a Director of Millicom (Tigo) Luxembourg, March 17, 2025 – International Cellular S.A. ("Millicom") announces that, on March 14, 2025, Atlas S.A.S. (”Atlas”) a person closely associated (”PCA”) with Jules Niel, a member of Millicom’s Board of Directors, informed that it acquired Millicom Swedish Depository Receipts (SDRs)in Nasdaq Stockholm as follows (the “Acquisition”): Date Price per unit Volume (units) 11 March 2025 299.23 SE...
Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer Media ReleaseCOPENHAGEN, Denmark; March 17, 2025 Results from Phase 2 RAINFOLTM-01 trial (B1 cohort) showed that with a median on-study follow-up of 48 weeks, Rina-S 120 mg/m2 led to a confirmed objective response rate (ORR) of 55.6% and median duration of response (mDOR) was not reached Phase 2 RAINFOLTM-01 and Phase 3 RAINFOLTM-02 trials evaluating the safety and efficacy of Rina-S at 120 mg/m2 in patients with platinum resistant ovarian cancer (PROC)...
Millicom (Tigo) share repurchase activity Millicom (Tigo) share repurchase activity Luxembourg, March 17, 2025 - Pursuant to the share repurchase program announced on November 29, 2024, Millicom repurchased 315,930 of its Swedish Depository Receipts (SDRs) and 736,800 of its common shares between March 10, 2025, and March 14, 2025, as detailed in the table below. Exchange Nasdaq Stockholm Nasdaq Stock Market Trade Date Number of SDRs repurchased Average price paid* (SEK) Repurchase amount* (SEK) Number of shares repurchased Average price paid* (USD) Repurchase amount* (USD) 20...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.